Education
About Us
Working with TipRanks
Follow Us
Tong Ren Tang Technologies Co Ltd Class H (HK:1666)
:1666
1666 Stock Chart & Stats
HK$4.49
-HK$0.01(-0.20%)
At close: 4:00 PM EST
HK$4.49
-HK$0.01(-0.20%)
Day’s Range― - ―
52-Week RangeHK$4.19 - HK$5.52
Previous CloseN/A
Volume468.00K
Average Volume (3M)1.05M
Market Cap
HK$5.66B
Enterprise ValueHK$2.60B
Total Cash (Recent Filing)HK$5.15B
Total Debt (Recent Filing)HK$2.41B
Price to Earnings (P/E)12.2
Beta0.83
Next Earnings
Mar 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.47%
Share Statistics
EPS (TTM)0.29
Shares Outstanding628,704,000
10 Day Avg. Volume1,287,300
30 Day Avg. Volume1,053,233
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)0.87
Price to Sales (P/S)0.86
P/FCF Ratio-39.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthMulti-year revenue growth near 7% demonstrates steady demand for the company’s TCM portfolio and supports durable top-line expansion. Persistent sales growth enables scale benefits, predictable planning, and reinvestment into R&D, distribution and brand-building over the medium term.
Low Leverage / Strong Capital StructureLow D/E and a high equity ratio provide financial flexibility and resilience to industry cycles. This capital structure reduces refinancing and solvency risk, enabling the company to fund organic growth, manage working capital, and support strategic initiatives without excessive interest burden.
High Gross Margin & Stable Operating MarginsA near-40% gross margin indicates structural pricing power or efficient production in TCM formulations. Coupled with stable EBIT/EBITDA margins, this suggests sustainable operational efficiency that can absorb input cost shocks and support long-term profitability and cash generation if revenue trends persist.
Bears Say
Declining Net Profit MarginA downward net margin trend signals rising costs, pricing pressure, or mix shifts that compress bottom-line profitability. If persistent, margin erosion reduces retained earnings and free cash generation, limiting capacity to invest, pay dividends, or absorb volatility without altering strategy or cost structure.
Inconsistent Cash Flow / No Reported FCF 2024Absence of free cash flow in 2024 points to cash conversion or timing issues that can impair the company's ability to self-fund capex, dividends, and strategic investments. Even with positive historical operating cash flow, inconsistent FCF elevates financing and operational risk over the medium term.
Material EPS DeclineA sharp decline in EPS indicates weaker per-share profitability that may stem from margin pressure, higher costs, or one-off items. Sustained EPS contraction can limit retained capital for growth, weaken investor confidence, and constrain ability to pursue acquisitions or expand distribution long term.
Tong Ren Tang Technologies Co News
1666 FAQ
What was Tong Ren Tang Technologies Co Ltd Class H’s price range in the past 12 months?
Tong Ren Tang Technologies Co Ltd Class H lowest stock price was HK$4.19 and its highest was HK$5.52 in the past 12 months.
What is Tong Ren Tang Technologies Co Ltd Class H’s market cap?
Tong Ren Tang Technologies Co Ltd Class H’s market cap is HK$5.66B.
When is Tong Ren Tang Technologies Co Ltd Class H’s upcoming earnings report date?
Tong Ren Tang Technologies Co Ltd Class H’s upcoming earnings report date is Mar 20, 2026 which is in 25 days.
How were Tong Ren Tang Technologies Co Ltd Class H’s earnings last quarter?
Tong Ren Tang Technologies Co Ltd Class H released its earnings results on Aug 26, 2025. The company reported HK$0.286 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.286.
Is Tong Ren Tang Technologies Co Ltd Class H overvalued?
According to Wall Street analysts Tong Ren Tang Technologies Co Ltd Class H’s price is currently Overvalued.
Does Tong Ren Tang Technologies Co Ltd Class H pay dividends?
Tong Ren Tang Technologies Co Ltd Class H pays a Annually dividend of HK$0.197 which represents an annual dividend yield of 4.47%. See more information on Tong Ren Tang Technologies Co Ltd Class H dividends here
What is Tong Ren Tang Technologies Co Ltd Class H’s EPS estimate?
Tong Ren Tang Technologies Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tong Ren Tang Technologies Co Ltd Class H have?
Tong Ren Tang Technologies Co Ltd Class H has 628,704,000 shares outstanding.
What happened to Tong Ren Tang Technologies Co Ltd Class H’s price movement after its last earnings report?
Tong Ren Tang Technologies Co Ltd Class H reported an EPS of HK$0.286 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.301%.
Which hedge fund is a major shareholder of Tong Ren Tang Technologies Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:1666
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tong Ren Tang Technologies Co Ltd Class H
Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China and Hong Kong. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, and foot care products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, cosmetics, and healthcare products; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food and daily chemical products, and medical services. The company was founded in 1669 and is based in Beijing, the People's Republic of China.
Technical Analysis
Beijing Tong Ren Tang Chinese Medicine Co
―
China Traditional Chinese Medicine Holdings Co
―
Abbisko Cayman Limited
―
China Shineway Pharmaceutical Group Limited
―
Reliance Global Holdings Limited
―
Options Prices
Currently, No data available
---